Reporting owner · CIK 0001134657
Evnin Luke
SEC Form 4 history across 2 companies, 15 transactions and 5 filings.
10%Entrada Therapeutics, Inc.
Open-market transaction mix0% buys0 buys · 15 sales
Available history · May 27, 2026 – Sep 09, 2026
Latest insider transactions
Form 4 filings from available history.Latest Form 4 facts
Quick context from source filings
Latest open-market transaction
sale at Entrada Therapeutics, Inc. on Sep 09, 2026 valued at $205,608.
Review SEC filingLatest buy
No open-market insider purchase is available.
Monthly open-market activity
Last 3 reported months · purchases and sales
View exact monthly values
| Month | Purchases | Sales | Buy value | Sale value | Net value |
|---|---|---|---|---|---|
| May 2026 | 0 | 3 | $0.00 | $66,200.24 | -$66,200.24 |
| Aug 2026 | 0 | 6 | $0.00 | $1,077,322.98 | -$1,077,322.98 |
| Sep 2026 | 0 | 6 | $0.00 | $2,523,146.69 | -$2,523,146.69 |
Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.
Ownership and transaction size
Ownership and ticket size
Average P/S size$244.4K
Median P/S size$200K
Direct0
Indirect15
Sep 09, 2026sale
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Companies in the disclosed reporting history
Open-market buy performance
90-day forward return on this insider's open-market purchases
No open-market purchases in available history
A 90-day purchase return requires an open-market buy. No eligible purchases are recorded in this history.
Disclosed ownership
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
12 observations · Aug 24, 2026 – Sep 9, 2026. Window ends at the latest available report, not today.
Selected observation · Sep 9, 20263,885,115 shares reported
Inspect transaction View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Aug 24, 2026 | 4,359,439 | Aug 27, 2026 | View transaction |
| Aug 25, 2026 | 4,332,917 | Aug 27, 2026 | View transaction |
| Aug 26, 2026 | 4,318,348 | Aug 27, 2026 | View transaction |
| Aug 27, 2026 | 4,279,426 | Aug 31, 2026 | View transaction |
| Aug 28, 2026 | 4,275,693 | Aug 31, 2026 | View transaction |
| Aug 31, 2026 | 4,231,434 | Aug 31, 2026 | View transaction |
| Sep 1, 2026 | 4,202,346 | Sep 3, 2026 | View transaction |
| Sep 2, 2026 | 4,177,215 | Sep 3, 2026 | View transaction |
| Sep 3, 2026 | 4,144,952 | Sep 3, 2026 | View transaction |
| Sep 4, 2026 | 4,106,452 | Sep 9, 2026 | View transaction |
| Sep 8, 2026 | 3,913,952 | Sep 9, 2026 | View transaction |
| Sep 9, 2026 | 3,885,115 | Sep 9, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Evnin Luke Insider Activity FAQ
SEC Form 4 context
Who is Evnin Luke?
Evnin Luke is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001134657.
Which companies has Evnin Luke reported transactions for?
Entrada Therapeutics, Inc., Werewolf Therapeutics, Inc., Aktis Oncology, Inc.
When was Evnin Luke's latest insider buy?
No open-market insider purchase is available for this period.
When was Evnin Luke's latest insider sale?
sale at Entrada Therapeutics, Inc. on Sep 09, 2026 valued at $205,608.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.